Why brain cancer is often resistant to immunotherapy

New findings could help make immunotherapies for brain cancer more effective. The team analyzed almost 200,000 individual immune cells in tumor samples taken from patients with glioma, the most common and aggressive type of primary brain cancer. The researchers describe four gene expression 'programs' -- sets of genes with coordinated activity -- that either suppress the immune system or make it more active. Defining and understanding what drives these programs could one day help researchers target them with new drugs to dial up or down specific parts of the immune system to improve patient response to immunotherapy.

source https://www.sciencedaily.com/releases/2025/02/250226163234.htm